Plain Language Summary
# DTC Act of 2025 Summary **What the Bill Would Do** The Drug-price Transparency for Consumers Act of 2025 would require pharmaceutical companies to display price information in their direct-to-consumer drug advertisements. Specifically, any ad for a prescription drug or biologic product covered by Medicare or Medicaid would need to clearly show the wholesale price for a 30-day supply. The ads could also note that actual patient costs may vary depending on individual insurance coverage. The requirement would not apply to drugs costing less than $35 for a one-month supply.
Companies that violate these rules could face civil penalties of up to $100,000 per violation. **Who It Affects and Current Status** This bill would directly affect pharmaceutical companies that advertise to consumers, as well as patients who see these ads on television, online, and in print media. The goal is to give consumers clearer information about drug costs before they talk to their doctors. Currently, the bill is in committee (S 229 in the 119th Congress), meaning it has been introduced but not yet voted on by the full Senate. Senator Richard Durbin (D-Illinois) sponsors the legislation.
CRS Official Summary
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Latest Action
Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)